La vacuna contra la viruela del mono utilizada en España provoca graves efectos adversos en 1 de cada 25 personas.

Original review summary

The review says ACAM2000, the vaccine linked to the one-in-25 claim, is not marketed or administered in Spain or Europe for mpox. It identifies IMVANEX as the vaccine used in Europe, including Spain, and says it does not share ACAM2000’s serious adverse-effect risks. [S1][S1]